In addition, the interpretation of in vivo results of enoxolone efficacy in mice with CDI was complicated by the compound causing adverse side effects (Fig. S8), namely weight loss and its well-documented antiinflammatory properties (reduction of tumor necrosis factor-alpha and interleukin-6 synthesis) (51, 52). The gene discussed is IL6; the disease is clostridium difficile infection.